L-Lysinate for Health & Longevity
Evidence Review created on 11/07/2026 using AI4L + evidence-mcp / Opus 5.5
Also known as: Lysinate, Lysine Salt
Motivation
L-lysinate is a salt form of L-lysine, an essential amino acid that the body cannot make and must take in from food. It appears on supplement labels in mineral compounds such as magnesium, calcium or zinc lysinate, and in some fast-dissolving pain relievers such as ibuprofen lysinate. In the gut, each of these releases ordinary lysine, so interest centres on what extra lysine, and the lysinate carrier itself, might add.
Lysine has decades of use as a self-selected supplement for cold sores, based on the idea that it competes with arginine, an amino acid the cold-sore virus relies on. It has also drawn interest for stress and anxiety and for calcium uptake and bone health. Its use as a carrier grew from efforts to make drugs and minerals dissolve and absorb more readily, and health-focused adults now meet it both as a stand-alone supplement and hidden inside mineral products.
This review examines the human evidence on L-lysinate and the lysine it delivers for health and longevity: the expected benefits, the risks, typical protocols, and how the salt form compares with plain lysine supplements.
Benefits - Risks - Protocol - Conclusion
Recommended Reading
This section lists five overview resources on lysine, the amino acid that every L-lysinate salt releases, from a practitioner protocol and narrative reviews.
-
Herpes and Shingles - Shayna Sandhaus
Protocol whose section on lysine, the component every lysinate releases, weighs mixed herpes trials and suggests 1–3 g/day with a low-arginine diet. Life Extension sells lysine supplements.
-
Lysine: Sources, Metabolism, Physiological Importance, and Use as a Supplement - Holeček, 2025
Comprehensive narrative review of lysine intake, transport, breakdown, supplement uses and adverse effects, including kidney toxicity data and the lysine–arginine competition that applies to every lysinate.
-
L-lysine: Its antagonism with L-arginine in controlling viral infection. Narrative literature review. - Pedrazini et al., 2022
Explains the proposed antiviral mechanism of lysine, the component lysinate salts release: competition with arginine for building the virus’s protein shell and increased arginine breakdown.
-
The metabolic roles, pharmacology, and toxicology of lysine - Flodin, 1997
Classic review of lysine monohydrochloride pharmacology, proposed cardiovascular and bone uses, and chronic-dose safety; still the baseline reference for lysine, the amino acid every lysinate salt releases in the gut.
-
Lysine for Herpes Simplex Prophylaxis: A Review of the Evidence - Mailoo & Rampes, 2017
Reviews herpes trials of oral lysine, the component every lysinate releases: doses below 1 g/day ineffective without a low-arginine diet, doses above 3 g/day subjectively helpful; flags theoretical cardiovascular and gallbladder cautions.
Content from Rhonda Patrick, Andrew Huberman and Lifespan.io is not listed: web and on-site searches found no material discussing lysine or lysinate supplementation. Peter Attia’s content mentions lysine only as an essential amino acid in protein quality, for example in an interview segment with Don Layman (Attia–Layman protein episode), without discussing supplementation. Chris Kresser covers lysine only briefly, within an episode on lipoprotein(a) (an inherited cholesterol-carrying particle linked to heart disease) (Kresser lipoprotein(a) episode).
Grokipedia
No dedicated L-lysinate article exists; this Lysine article covers chemistry, transport, metabolism, dietary sources, supplementation and disease roles of the amino acid every lysinate releases.
Examine
Examine has no lysinate-specific page. Its Lysine page judges lysine of little promise beyond easing herpes symptoms and gives a herpes dose of up to 2 g/day, divided, with meals.
ConsumerLab
Independent quality testing of L-lysine products with top picks, dosage and cold-sore evidence; no lysinate-specific review exists. Full results require membership.
Systematic Reviews
These systematic reviews and meta-analyses cover oral L-lysine, the component every lysinate salt releases, and fast-acting ibuprofen salts including ibuprofen lysinate.
-
Interventions for prevention of herpes simplex labialis (cold sores on the lips). - Chi et al., 2015
Cochrane review of 32 randomized trials; found no evidence that lysine prevents cold sores, whereas long-term oral antivirals had a small preventive effect.
-
Comprehensive Safety Assessment of l-Lysine Supplementation from Clinical Studies: A Systematic Review. - Hayamizu et al., 2020
Amino-acid-industry-sponsored review of 71 studies (3,357 participants): no significant gastrointestinal excess; proposes 6.0 g/day as the no-observed-adverse-effect level (highest dose without observed harm).
-
Faster, higher, stronger? Evidence for formulation and efficacy for ibuprofen in acute pain. - Moore et al., 2014
Fast-acting ibuprofen formulations, including the lysine salt, peaked within 29–35 minutes and gave better 6-hour pain relief than standard ibuprofen in over 10,000 patients.
-
Nutritional and herbal supplements for anxiety and anxiety-related disorders: systematic review. - Lakhan & Vieira, 2010
Rated combined L-lysine and L-arginine among supplements with strong evidence for anxiety; lysine was not tested alone.
-
Nutraceuticals and phytoceuticals in the treatment of schizophrenia: a systematic review and network meta-analysis “Nutra NMA SCZ”. - Fornaro et al., 2025
Network meta-analysis (comparing many treatments jointly) of 50 add-on trials; L-lysine beat placebo on total schizophrenia symptoms; evidence quality rated low to very low.
Mechanism of Action
L-lysinate is L-lysine minus a proton, paired with a positive partner: a mineral (magnesium, calcium, zinc or iron lysinate) or an acidic drug (ibuprofen or aspirin lysinate). In the gut the pair separates, releasing lysine.
- Absorption and distribution: cationic amino acid transporters (carrier proteins shared with arginine) move lysine into cells, reaching up to five times plasma levels, per a review (Holeček 2025); lysine has no single receptor target.
- Metabolism: the liver degrades lysine in mitochondria (cell energy units) via the saccharopine pathway (the main lysine breakdown route), starting with aminoadipic semialdehyde synthase (the enzyme committing lysine to breakdown); cytochrome P450 enzymes (the main drug-metabolizing enzymes) play no role. No half-life is published.
- Building blocks: lysine supplies protein, collagen cross-links and carnitine (a fat-transport molecule).
- Arginine competition: excess lysine limits arginine entry into cells, the proposed cold-sore rationale, since herpes viruses need arginine, per a review (Pedrazini 2022); in animals it also lowers nitric oxide (a blood-vessel-relaxing signal), per a review (Holeček 2025).
- Calcium handling: lysine raised calcium absorption in osteoporotic patients and cut urinary calcium loss in healthy women (Civitelli 1992).
- Serotonin signaling: in rat studies by Ajinomoto, a lysine manufacturer, lysine partly blocked the 5-HT4 receptor (a gut and brain serotonin receptor), reducing anxiety (Smriga 2003).
- Carrier effect: as a counter-ion (the oppositely charged salt partner), lysinate speeds ibuprofen absorption (Ferrero-Cafiero 2015).
Countering the antiviral rationale, a 1.2 g/day trial found no effect (DiGiovanna 1984); at 1 g/day, benefit tracked serum lysine above 165 nmol/mL (Thein 1984).
Historical Context & Evolution
Lysine is an essential amino acid: the body cannot make it. More than 60 years ago it was shown to be the first limiting amino acid (the amino acid in shortest supply relative to need) in cereals, and lysine fortification of wheat-based diets became a tool against protein malnutrition in poor countries, per a review (Holeček 2025).
Interest for health optimization grew from three lines of work:
- Cold sores: cell-culture findings that herpes viruses depend on arginine led to oral lysine trials in the 1980s, with split findings, positive (Griffith 1987) and negative (DiGiovanna 1984), still unresolved.
- Artery health: Matthias Rath and Linus Pauling proposed that lipoprotein(a) substitutes for vitamin C in artery repair (Rath 1990) and promoted lysine with vitamin C to limit its deposition; no human outcome trial followed.
- Stress: researchers at Ajinomoto, a lysine manufacturer, linked lysine shortage to anxiety in rats and then tested fortified wheat in Syrian villages (Smriga 2004).
Pharmaceutical chemists used lysine as a counter-ion to make acidic drugs dissolve faster, producing ibuprofen lysinate and injectable aspirin lysinate. Supplement makers later bound minerals to lysine, and the European Food Safety Authority evaluated magnesium, calcium and zinc L-lysinate as mineral sources in 2008 (EFSA scientific opinion).
Scientific opinion has shifted as larger reviews arrived: a Cochrane review found no preventive effect on cold sores (Chi 2015), while proponents point to the positive higher-dose trials. Neither side has a decisive trial.
Expected Benefits
High 🟩 🟩 🟩
Acute Pain Relief with Drug Lysinates ⭕️ Not Central to Health & Longevity
Drug lysinates deliver anti-inflammatory pain relievers. In single-dose placebo-controlled dental-surgery trials, ibuprofen lysinate relieved moderate-to-severe pain for three research groups, led by Nelson (Nelson 1994), Mehlisch (Mehlisch 1995; shares a co-author with Nelson) and Kyselovič (Kyselovič 2020; Sanofi-authored). Intravenous aspirin lysinate relieved migraine better than placebo, though less than injected sumatriptan (a standard migraine drug) (Diener 1999). Oral aspirin lysinate combined with metoclopramide (an anti-nausea drug) also beat placebo for migraine (Chabriat 1994; Tfelt-Hansen 1995). Aspirin data are indirect (DL-lysine salt); the item bears on short-term pain relief, not longevity.
Magnitude: 6-hour total pain-relief score 11.31 points higher with ibuprofen lysinate than with placebo after one dose (95% confidence interval, the range likely to contain the true effect, 8.45–14.16; Kyselovič 2020); migraine reduced from severe or moderate to mild or none in 73.9% with intravenous aspirin lysinate versus 23.8% with placebo, no 95% confidence interval reported (Diener 1999).
Closure of Patent Ductus Arteriosus in Premature Infants ⭕️ Not Central to Health & Longevity
Intravenous ibuprofen lysine (NeoProfen) is approved to close a patent ductus arteriosus (a fetal blood vessel that stays open after premature birth) (NeoProfen label). Placebo-controlled trials from two research groups agree: one led by Aranda in 136 extremely low-birth-weight infants, co-authored by industry staff (Farmacon IL, Abbott Laboratories), found fewer needing rescue treatment (Aranda 2009); one led by Van Overmeire, also an Aranda co-author, in 415 preterm infants found more closed ducts (Van Overmeire 2004). This bears on newborn care, not adult longevity.
Magnitude: Ductus closed by day 3 in 84% with ibuprofen lysine versus 60% with placebo (relative risk, the chance with treatment divided by the chance with placebo, 1.40; 95% confidence interval 1.23–1.59; Van Overmeire 2004); 30.9% versus 52.9% reached the combined endpoint of rescue treatment, death or dropout by day 14, no 95% confidence interval reported (Aranda 2009).
Medium 🟩 🟩
No benefit reaches Medium: the remaining human trials tested DL-lysine aspirin salts, plain lysine, lysine-fortified food or lysine combinations, all indirect for L-lysinate, or gave conflicting results for ibuprofen lysinate.
Low 🟩
Relief of Rheumatoid Arthritis Symptoms with Aspirin Lysinate ⭕️ Not Central to Health & Longevity
Aspirin lysinate is approved in France for inflammatory rheumatism (ANSM SmPC Aspégic). In a small double-blind crossover trial (each patient took both drugs in turn), lysine acetylsalicylate relieved rheumatoid arthritis symptoms like ibuprofen, with more drug-related withdrawals (Hill 1990). Indirect: DL-lysine salt. This bears on joint symptom relief, not longevity.
Magnitude: Of patients stating a preference, 8 of 10 chose lysine acetylsalicylate over ibuprofen for mobility (Hill 1990) and 15 of 24 for pain (Hill 1990); no symptom-score difference or 95% confidence interval is reported in the source summary (Hill 1990).
Fewer Heart Attacks, Strokes and Bypass-Graft Blockages with Aspirin Lysinate
Kardégic (DL-lysine aspirin) has French approval against repeat heart attacks and strokes, bypass-graft blockage, and atrial fibrillation (irregular heart rhythm) strokes (ANSM SmPC Kardégic). Meta-analyses support aspirin for vascular events (Baigent 2009), antiplatelet (clot-preventing) drugs for graft blockage (Antiplatelet Trialists’ Collaboration 1994) and atrial-fibrillation stroke (Hart 2007). Indirect: plain-aspirin trials.
Magnitude: Major coronary events (heart attack or coronary death) in 4.3% versus 5.3% per year with aspirin versus control across secondary-prevention trials (rate ratio, the event rate with aspirin divided by the rate without, 0.80; 95% confidence interval 0.73–0.88; Baigent 2009); coronary graft occlusion in 21% with antiplatelet therapy versus 30% with control, no 95% confidence interval in the source summary (Antiplatelet Trialists’ Collaboration 1994); stroke 22% lower with antiplatelet agents versus control in atrial fibrillation (95% confidence interval 6–35%), with no per-group rates in the source summary (Hart 2007).
Fewer Recurrent Colorectal Adenomas with Aspirin Lysinate ⚠️ Conflicted
Aspirin DL-lysinate 160–300 mg/day reduced recurrent colorectal adenomas (precancerous bowel polyps) over 5 mm at 1 year versus placebo (Benamouzig 2003); 4-year any-adenoma recurrence did not differ (Benamouzig 2012). A meta-analysis pooling this and three plain-aspirin trials found fewer adenomas (Cole 2009). Indirect: DL-lysine salt. Net: early signal, unsustained.
Magnitude: Adenomas larger than 5 mm in 10% with aspirin lysinate versus 23% with placebo at 1 year, no 95% confidence interval reported (Benamouzig 2003); any adenoma in 41% versus 40% at 4 years (Benamouzig 2012); pooled risk ratio (risk with aspirin divided by risk with placebo) 0.83 for any adenoma with aspirin at any dose versus placebo across the four trials (95% confidence interval 0.72–0.96), 33% versus 37% (Cole 2009).
Fewer Cold-Sore Recurrences ⚠️ Conflicted
Lysine may deprive the herpes simplex virus of arginine. Lysine-hydrochloride trials at 3 g/day (Griffith 1987) and 1.2 g/day (McCune 1984) reported fewer recurrences, but DiGiovanna 1984 and a Cochrane review (Chi 2015) found no benefit. No trial tested a lysinate salt. Net: benefit possible at 3 g/day, unproven.
Magnitude: 2.4 fewer outbreaks on average than placebo over 6 months at 3 g/day (Griffith 1987; no 95% confidence interval, the range likely to contain the true effect, reported); no substantial difference at 1.2 g/day (DiGiovanna 1984).
Lower Anxiety and Stress-Hormone Responses ⚠️ Conflicted
Lysine-fortified wheat lowered trait anxiety (habitual anxiety level) in men and blood-draw cortisol (stress hormone) responses in women (Smriga 2004); lysine plus arginine lowered anxiety (Smriga 2007) but heightened hormonal stress responses (Jezova 2005). All three were Ajinomoto-linked. Indirect: fortified food, arginine. Net: anxiety signal plausible; hormonal effects inconsistent.
Magnitude: Trait-anxiety questionnaire score fell by 6.9 ± 1.8 points (mean ± standard error, the precision of the mean) from before to after 3 months within the fortified men, with no control-group change given in the text, not compared between groups (Smriga 2004); no effect in women (Smriga 2004); no 95% confidence interval reported.
Higher Intestinal Calcium Absorption
Lysine hydrochloride raised calcium absorption in osteoporosis (Civitelli 1992); lysine plus arginine showed a trend (Bihuniak 2014). An unblinded calcium lysinate trial of 24 people (two authors from Puneet Laboratories) reported higher uptake than calcium carbonate, comparing bone density only within groups (Shankar 2018). Lysine-hydrochloride data are indirect.
Magnitude: Calcium lysinate produced 223% of calcium carbonate’s dose-adjusted serum-calcium area under the curve (total rise over time) after one dose, with no 95% confidence interval (Shankar 2018); heel bone-density scores improved within each group (p-value, the probability the change is chance: lysinate p<0.0004, carbonate p<0.0042, calcium citrate malate p<0.0069), not compared between groups (Shankar 2018).
Smaller Blood-Sugar Rise After Meals ⚠️ Conflicted
Lysine blunted the glucose rise after a glucose drink (Kalogeropoulou 2009) and lowered 60-minute, not total, glucose after a mixed drink (Ullrich 2017). Eight weeks of high-lysine diet left fasting glucose and insulin sensitivity unchanged (Unni 2012). Indirect: free lysine, not lysinate. Net: acute effect shown; lasting benefit unproven.
Magnitude: 2.5-hour glucose response 44% lower with lysine plus glucose than with glucose alone, crossover design (each person received both), no 95% confidence interval (Kalogeropoulou 2009).
Faster Drug Absorption as a Lysinate Salt ⚠️ Conflicted ⭕️ Not Central to Health & Longevity
Lysinate speeds ibuprofen absorption (Ferrero-Cafiero 2015). A systematic review found fast-acting ibuprofen salts relieved pain better than standard ibuprofen (Moore 2014); a 351-patient dental trial found lysinate no better than ibuprofen acid (Kyselovič 2020; Sanofi-authored). This bears on pain relief, not longevity. Net: likely modest clinical gain, unconfirmed for lysinate.
Magnitude: S-ibuprofen (the active form) peaked at 0.5 versus 1.33 hours for lysinate versus standard suspension, fasting crossover, no 95% confidence interval (Ferrero-Cafiero 2015); 6-hour total pain-relief score 0.39 points lower with lysinate than with ibuprofen acid (95% confidence interval −2.74 to 1.96), not significantly different (Kyselovič 2020).
Fever Reduction with Drug Lysinates ⭕️ Not Central to Health & Longevity
Aspirin lysinate is approved in France for pain and fever (ANSM SmPC Aspégic). A narrative review of pediatric comparative trials rated ketoprofen lysine salt a valuable fever option (Scaglione 2025). Indirect: aspirin’s action via a DL-lysine salt; ketoprofen acid pooled with the salt. This bears on symptom relief, not longevity.
Magnitude: Fever falls at standard fever-reducing doses, but the cited review reports no outcome figure, and no placebo-controlled fever trial of a drug lysinate was found (Scaglione 2025).
Reduced Schizophrenia Symptoms as an Add-On ⭕️ Not Central to Health & Longevity
Oral lysine at 6 g/day added to antipsychotic drugs (medicines for psychosis) improved symptoms in a 72-patient Iranian trial (Zeinoddini 2014); a 10-patient pilot was inconclusive (Wass 2011); a network meta-analysis found benefit (Fornaro 2025). Indirect: lysine, not lysinate. This bears on psychiatric treatment, not longevity.
Magnitude: Total symptom score standardized mean difference (effect size in standard-deviation units) of −1.04 versus placebo (95% confidence interval −1.84 to −0.25; Fornaro 2025).
Kidney Protection During Radioactive Cancer Therapy ⭕️ Not Central to Health & Longevity
A lysine–arginine infusion (LysaKare) is EU-approved to shield the kidneys during lutetium-177 oxodotreotide therapy for neuroendocrine tumors (hormone-producing gut or pancreas tumors) (EMA SmPC LysaKare). It lowered kidney radioactivity versus patients’ own uninfused scans (Rolleman 2003). Indirect: intravenous lysine hydrochloride with arginine. This bears on cancer-treatment safety, not longevity.
Magnitude: Kidney radioactivity at 24 hours 33% lower on average with 25 g lysine plus 25 g arginine than without infusion in the same patients, no 95% confidence interval reported (Rolleman 2003).
Speculative 🟨
Less Protein Glycation
In type 2 diabetes, 3 g/day lysine added to drug treatment lowered glycation (sugar damage to proteins) markers and protected lysozyme (an antibacterial enzyme) (Mirmiranpour 2016). These are unvalidated laboratory markers.
Protection Against Lipoprotein(a)-Driven Artery Disease
Rath and Pauling’s hypothesis that lipoprotein(a) substitutes for vitamin C in artery repair (Rath 1990) was later extended to lysine blocking its deposition in artery walls. The basis is mechanistic; no human outcome trial exists.
Benefit-Modifying Factors
- Genetic variation: no study links lysine response to common gene variants. In lysinuric protein intolerance (inherited SLC7A7 transporter defect blocking lysine uptake), small mealtime lysine doses still raised plasma lysine without harm (Tanner 2007).
- Baseline lysine intake: the fortification trial enrolled only people eating lysine-poor, cereal-based diets (Smriga 2004); a review notes little added effect from supplementing a lysine-sufficient diet (Holeček 2025).
- Serum lysine level: fewer cold-sore recurrences occurred when serum lysine stayed above 165 nmol/mL (Thein 1984).
- Sex: fortification lowered anxiety in men but cortisol responses in women (Smriga 2004); lysine plus arginine lowered salivary cortisol only in men (Smriga 2007); oral aspirin lysinate was absorbed faster in women (Aarons 1989).
- Pre-existing conditions: benefit signals come from people with frequent cold sores, osteoporosis, high trait anxiety or diabetes; lysine blunted urinary calcium loss in healthy women but not clearly in osteoporotic women (Civitelli 1992).
- Age: trials mostly enrolled adults under 60, and no age-stratified data exist; older adults with lower kidney reserve face a narrower margin between helpful and harmful doses.
Potential Risks & Side Effects
High 🟥 🟥 🟥
Kidney Strain with Drug Lysinates ⚠️ Conflicted
Drug lysinates share parent-drug kidney effects via reduced kidney blood flow. Placebo-controlled infant trials of ibuprofen lysinate led by Aranda and Van Overmeire concur: the label reports more kidney adverse events in Aranda’s (NeoProfen label), though its report found no fluid-output difference (Aranda 2009); Van Overmeire’s found lower urine output and higher creatinine (Van Overmeire 2004). A meta-analysis of adult observational studies links ibuprofen-class drugs to kidney injury (Ungprasert 2015); aspirin lysinate’s label lists kidney failure (ANSM SmPC Kardégic). Net: replicated kidney signal; fluid balance unchanged in one report.
Magnitude: Kidney adverse events in 21% of premature infants given NeoProfen versus 15% given placebo within 30 days (NeoProfen label); pooled risk ratios (risk in users divided by risk in non-users) of 1.58–2.11 for acute kidney injury across traditional anti-inflammatory drugs, ibuprofen included, versus non-users, with no per-group event rates in the source summary (Ungprasert 2015).
Medium 🟥 🟥
Stomach and Gut Injury with Drug Lysinates
Drug lysinates share their parent anti-inflammatory drugs’ gut risks from blocked stomach-protective signaling. In a placebo-controlled endoscopic trial in 45 volunteers, ibuprofen lysinate 800 mg/day for 3 days raised gastric erosion (shallow stomach-lining damage) and bleeding scores above placebo, though below aspirin 2,000 mg/day (Müller 1994). A week of DL-lysine aspirin (indirect) caused about half plain aspirin’s gastric lesions in a small trial (Bretagne 1984). In premature infants, NeoProfen’s label lists gut perforation and necrotizing enterocolitis (intestinal tissue death) (NeoProfen label). Plain lysine and mineral lysinates are not implicated.
Magnitude: Duodenal erosions in 6% with ibuprofen lysinate versus 0% with placebo, not significantly different (Müller 1994); mean gastric erosion and bleeding scores were significantly higher than placebo, with no group figures or 95% confidence interval in the source summary (Müller 1994).
Other Adverse Events in Premature Infants with Ibuprofen Lysinate
Ibuprofen lysinate’s label lists adverse events more frequent than with placebo within 30 days of its premature-infant trial: anemia, hypoglycemia (low blood sugar), hypocalcemia (low blood calcium), hypernatremia (high blood sodium), apnea (breathing pauses), edema, respiratory failure and adrenal insufficiency (low stress-hormone output) (NeoProfen label). The label reports no statistical test for these differences. The trial’s published report found no difference in death or chronic lung disease (Aranda 2009). This applies to premature infants, not adults.
Magnitude: In premature infants given NeoProfen versus placebo within 30 days: anemia in 32% versus 25% (NeoProfen label), hypoglycemia in 12% versus 6% (NeoProfen label), respiratory failure in 10% versus 4% (NeoProfen label) and adrenal insufficiency in 7% versus 1% (NeoProfen label); the label gives no 95% confidence interval.
Low 🟥
Gastrointestinal Upset ⚠️ Conflicted
Nausea, stomach pain and diarrhea are the main lysine-trial complaints (Hayamizu 2019); up to 7.5 g dose-dependently increased intestinal fluid in a small crossover study (Baruffol 2014). An amino-acid-industry-funded review of 71 studies found no excess over control (Hayamizu 2019). Indirect: lysine, not lysinate. Net: uncommon below 6 g/day.
Magnitude: Pooled risk ratio (risk with lysine divided by risk without) of 1.02 for gastrointestinal symptoms versus control groups (95% confidence interval 0.96–1.07; Hayamizu 2019); per-group event rates are not reported in the source summary.
Kidney Tubule Injury
A woman taking 3 g/day lysine for 5 years developed Fanconi syndrome (kidney tubules leaking glucose, amino acids and phosphate) and tubulointerstitial nephritis (kidney inflammation), progressing to kidney failure (Lo 1996). A review reports tubule injury from high intravenous lysine in rats and dogs (Holeček 2025). Indirect: lysine, not lysinate.
Magnitude: Not quantified in available studies. Only a single human case report exists, without a comparison group, and the animal data used intravenous doses.
Heart and Vascular Events with Ibuprofen Lysinate
Ibuprofen, the parent drug of ibuprofen lysinate, raised major coronary events (heart attack or coronary death) and roughly doubled heart failure risk in a meta-analysis of randomized trials (Bhala 2013). The lysine carrier does not remove this parent-drug risk. Indirect: ibuprofen in any form, mainly high doses, not lysinate-specific.
Magnitude: Rate ratio (event rate with the drug divided by the rate with placebo) of 2.22 for major coronary events with high-dose ibuprofen versus placebo (95% confidence interval 1.10–4.48; Bhala 2013); per-group event rates are not reported in the source summary.
Bleeding with Drug Lysinates ⚠️ Conflicted
Aspirin and ibuprofen lysinates inhibit platelets. Aspirin lysinate’s label lists sometimes fatal brain bleeding (ANSM SmPC Kardégic); pooled plain-aspirin trials showed more bleeding outside the skull (Baigent 2009). Indirect: aspirin, not lysinate. Ibuprofen lysinate’s infant trial showed little excess (NeoProfen label). Net: clear with aspirin lysinate, little with ibuprofen lysinate.
Magnitude: Major gastrointestinal and other extracranial (outside the skull) bleeds in 0.10% versus 0.07% per year with aspirin versus control in primary-prevention trials (rate ratio 1.54, 95% confidence interval 1.30–1.82; Baigent 2009); hemorrhagic stroke (brain bleeding) in 0.04% versus 0.03% per year in the same trials (Baigent 2009); bleeding of any kind in 32% of premature infants given NeoProfen versus 29% given placebo within 30 days (NeoProfen label).
Asthma and Allergic Reactions with Aspirin Lysinate
Aspirin lysinate’s French label rules it out after aspirin-provoked asthma and lists bronchospasm (airway narrowing), anaphylaxis (severe whole-body allergic reaction), hives, fixed skin eruptions and Kounis syndrome (allergy-triggered heart attack) (ANSM SmPC Kardégic). A systematic review found aspirin-induced asthma common in adults with asthma (Jenkins 2004). Indirect: plain aspirin.
Magnitude: Aspirin-induced asthma in 21% of adults with asthma on oral provocation testing (95% confidence interval 14–29%), pooled across studies, no control group (Jenkins 2004); 98% of those affected also reacted to ibuprofen (Jenkins 2004).
Serious Skin and Hypersensitivity Reactions with Ibuprofen Lysinate
Ibuprofen lysinate’s label warns of sometimes fatal skin reactions, Stevens-Johnson syndrome and toxic epidermal necrolysis (widespread skin blistering and peeling), and lists post-marketing DRESS (drug rash with organ involvement) (NeoProfen label). A case-control study (cases versus matched unaffected people) found low absolute risk (Mockenhaupt 2003). Indirect: anti-inflammatory class data.
Magnitude: Not quantified in available studies. No trial of ibuprofen lysinate has measured these reactions, DRESS is known only from post-marketing reports, and the case-control study summary gives no ibuprofen-specific figure.
Liver Injury with Aspirin Lysinate
A 75-year-old woman taking aspirin lysinate 1 g/day for 5 years was hospitalized with liver cirrhosis (permanent liver scarring) and granulomatous hepatitis (liver inflammation with immune-cell clusters); liver tests normalized after stopping it (D’Abrigeon 1995). She took other drugs concurrently. Evidence is one case report. Indirect: DL-lysine salt.
Magnitude: Not quantified in available studies. Only a single case report exists, without a comparison group.
Gout Attacks with Aspirin Lysinate
Aspirin lysinate’s French label states low-dose aspirin reduces uric acid excretion, which can trigger gout attacks (ANSM SmPC Kardégic). In a case-crossover study (pre-attack days compared with each person’s attack-free days) of 724 people with gout, two consecutive low-dose aspirin days preceded more attacks (Zhang 2014). Indirect: plain aspirin.
Magnitude: Odds ratio (odds of an attack with aspirin divided by odds without) of 1.81 for recurrent gout attacks with up to 325 mg/day aspirin on two consecutive days versus no aspirin (95% confidence interval 1.30–2.51), comparing each person’s own aspirin and aspirin-free periods; absolute attack rates are not reported in the source summary (Zhang 2014).
Pulmonary Hypertension in Premature Infants with Ibuprofen Lysinate
Ibuprofen lysinate’s label lists pulmonary hypertension (raised blood pressure in the lung arteries) among post-marketing reports in premature infants (NeoProfen label). A placebo-controlled trial of preventive intravenous ibuprofen in very premature infants stopped early after three severe cases (Gournay 2004). Indirect: the trial summary does not name the ibuprofen salt.
Magnitude: Severe pulmonary hypertension in 3 of 65 infants given preventive ibuprofen, which stopped the trial; the source summary gives no placebo-group count (Gournay 2004), and the label gives no rate for its post-marketing reports (NeoProfen label).
Infection Masking and Sepsis in Premature Infants with Ibuprofen Lysinate ⚠️ Conflicted
Ibuprofen lysinate’s label warns it may mask signs of infection and reports more sepsis (bloodstream infection with organ dysfunction) than placebo in its infant trial (NeoProfen label). A larger placebo-controlled trial noted no important side-effect differences (Van Overmeire 2004). Net: a label signal unconfirmed by the larger trial.
Magnitude: Sepsis in 43% of premature infants given NeoProfen versus 37% given placebo within 30 days (NeoProfen label); the larger trial’s summary gives no sepsis figures (Van Overmeire 2004).
Hemolysis in G6PD Deficiency with Aspirin Lysinate ⚠️ Conflicted
Aspirin lysinate’s label lists hemolytic anemia (red-cell destruction) with G6PD deficiency (inherited defect in a red-cell protective enzyme) (ANSM SmPC Kardégic). On 100 mg/day aspirin, one deficient stroke patient had acute hemolysis (Chen 2021); a series of 44 found none (Shalev 1991). Indirect: plain aspirin. Net: rare at low doses.
Magnitude: Acute hemolysis in 1 of 81 G6PD-deficient versus 0 of 576 G6PD-normal stroke patients over three months on 100 mg/day aspirin, not significantly different (Chen 2021).
Tinnitus and Hearing Loss with High-Dose Aspirin Lysinate
Aspirin lysinate’s French label lists ringing in the ears (tinnitus) and reduced hearing during long-term high-dose use, usually a sign of overdose (ANSM SmPC Kardégic). In a double-blind dose-ranging trial in eight volunteers, both rose progressively with aspirin dose (Day 1989). Indirect: plain aspirin, not lysinate.
Magnitude: Hearing loss and tinnitus intensity rose progressively from 1.95 to 5.85 g/day aspirin, with hearing loss tracking unbound salicylate linearly; the source summary reports no outcome figure, and the trial had no placebo group (Day 1989).
Blood-Cell Disorders with Aspirin Lysinate
Aspirin lysinate’s French label lists low platelet counts, pancytopenia (loss of all blood-cell types), aplastic anemia (bone-marrow failure) and agranulocytosis (loss of infection-fighting white cells) (ANSM SmPC Kardégic). A case report attributed pancytopenia to aspirin-induced bone-marrow damage (Wijnja 1966). Indirect: plain aspirin, not lysinate.
Magnitude: Not quantified in available studies. The label gives no frequency, and the only human evidence is a case report without a comparison group.
Reye’s Syndrome in Children and Adolescents with Aspirin Lysinate
Aspirin lysinate’s French label warns of Reye’s syndrome (acute brain and liver injury), very rare but life-threatening, in children and adolescents with viral infections like chickenpox or influenza (ANSM SmPC Kardégic). A case-control study linked it strongly to aspirin taken during these illnesses (Hurwitz 1987). Indirect: plain aspirin.
Magnitude: Odds ratio of 26 for Reye’s syndrome with aspirin during the preceding illness versus no aspirin (lower 95% confidence limit 6.4; 27 cases versus 140 matched controls), with no absolute rates in the source summary (Hurwitz 1987); case fatality 31% among 1,207 reported US cases, no control group (Belay 1999).
Fetal Harm in Late Pregnancy with Drug Lysinates
Aspirin lysinate’s label warns that doses above 100 mg/day from 24 weeks of pregnancy can cause fetal death, even after one dose, by narrowing the fetal ductus arteriosus and reducing amniotic fluid (ANSM SmPC Kardégic). A meta-analysis linked late-pregnancy anti-inflammatory drugs to premature ductal closure (Koren 2006). Indirect: mostly indomethacin.
Magnitude: Odds ratio of 15.04 for premature ductal closure with late-pregnancy anti-inflammatory drugs, mainly indomethacin, versus placebo or other drugs (95% confidence interval 3.29–68.68), pooled across 8 studies; the source summary gives no per-group rates (Koren 2006).
High Blood Potassium with Infused Lysine and Arginine
The EU-approved lysine–arginine infusion (LysaKare) is associated with hyperkalemia (high blood potassium, which can disturb heart rhythm) of unknown frequency, rules out use with uncorrected hyperkalemia, and very commonly causes nausea and vomiting (EMA SmPC LysaKare). A safety study confirmed transient potassium rises (Hofland 2026). Indirect: intravenous lysine hydrochloride.
Magnitude: Treatment-related hyperkalemia in 5 of 41 patients (12.2%; one severe), all resolved within 24 hours (Hofland 2026); mean potassium rose 0.60 mmol/L at 4 hours (Hofland 2026); single-arm study, no control group.
Other Label-Listed Reactions with Aspirin Lysinate
Aspirin lysinate’s French label lists vasculitis (blood-vessel inflammation), non-cardiogenic pulmonary edema (fluid in the lungs), acute pancreatitis, and headache or vertigo at high doses (ANSM SmPC Kardégic). In salicylate poisoning, non-cardiogenic pulmonary edema was frequent in patients over 30 (Walters 1983). Indirect: plain aspirin and salicylate overdose.
Magnitude: Non-cardiogenic pulmonary edema in 35% of salicylate-poisoned patients over 30 years old, no control group (Walters 1983); the label gives no frequencies for these reactions.
Speculative 🟨
Reduced Arginine Availability and Nitric Oxide
High lysine competes with arginine for cell entry and lowered nitric oxide production in cell and rat studies summarized in a review (Holeček 2025). Effects on human blood flow are untested.
Concerns in Cardiovascular and Gallbladder Disease
A review advises caution in cardiovascular or gallbladder disease, citing theoretical risks of lysine supplementation (Mailoo 2017). The basis is mechanistic; no human outcome data exist.
Bilirubin Displacement in Premature Infants with Ibuprofen Lysinate ⚠️ Conflicted
Ibuprofen lysinate’s label warns ibuprofen displaces bilirubin (red-cell breakdown pigment) from albumin (NeoProfen label), as laboratory tests show (Soligard 2010). In 34 preterm infants, unbound bilirubin did not rise (Desfrere 2012). Net: unconfirmed in infants.
Risk-Modifying Factors
- Genetic disorders of lysine breakdown: glutaric aciduria type 1 (Boy 2023) and pyridoxine-dependent epilepsy (Coughlin 2021) (GCDH and ALDH7A1 gene defects; both enzymes break down lysine) make extra lysine harmful, per consensus guidelines; hyperlysinemia (inherited high blood lysine) is a listed contraindication (Drugs.com lysine monograph).
- Baseline kidney function: reduced kidney function raises risk; the Drugs.com lysine monograph advises avoidance in renal impairment, and the single kidney-failure case followed years of 3 g/day (Lo 1996).
- Baseline calcium status: lysine raised calcium absorption and, in healthy women, cut urinary calcium loss (Civitelli 1992); with high-normal serum calcium or high calcium intake, particularly from calcium lysinate, this adds to the calcium load, an inference that study did not test.
- Sex: no sex difference in lysine side effects has been reported; the one kidney case was a woman, which cannot establish a pattern; aspirin lysinate absorption differs by sex (Aarons 1989).
- Pre-existing conditions: liver impairment (lysine is broken down almost entirely in the liver) per the Drugs.com lysine monograph; cardiovascular or gallbladder disease, per a review (Mailoo 2017).
- Drug lysinates: ibuprofen lysinate still caused gastric erosions versus placebo (Müller 1994); drug salts carry their parent drug’s full risk profile.
- Age: no age-stratified safety data exist; older adults usually have less kidney reserve, which matters given the kidney signal.
Key Interactions & Contraindications
Documented interactions:
- Calcium supplements and calcium-based antacids (calcium carbonate, calcium citrate): lysine raised intestinal calcium absorption in osteoporotic patients and blunted urinary calcium loss in healthy women (Civitelli 1992). Consequence: higher calcium load. Mitigation: counting calcium from all sources, including calcium lysinate itself.
- Meals with drug lysinates (ibuprofen lysinate): after food, ibuprofen lysinate lost its earlier, higher peak (Weiser 2019, Sanofi-authored). Consequence: slower onset of pain relief. Mitigation: fasting use when speed matters and the drug label permits.
- Carbohydrate-rich meals and glucose drinks: lysine taken with glucose lowered the blood-glucose response (Kalogeropoulou 2009), and lysine before a mixed drink lowered 60-minute glucose (Ullrich 2017). Consequence: smaller glucose rise. Mitigation: glucose checks if combined with glucose-lowering drugs.
- Levodopa (Parkinson’s disease drug): lysine at 100 mg/kg did not reverse the clinical effect of infused levodopa, unlike large neutral amino acids (Nutt 1984). No interaction found; no mitigation needed.
- Oral anticoagulants (blood-clot-preventing drugs) with ibuprofen lysinate or lysine clonixinate (warfarin, acenocoumarol, phenprocoumon): human studies found no interaction with ibuprofen lysinate (Marini 1985) or with lysine clonixinate (an anti-inflammatory pain reliever) (Russmann 2001). No interaction found; the parent drug’s label still governs combined use.
- Oral anticoagulants and methotrexate with aspirin lysinate (warfarin; methotrexate above 20 mg/week): its French label advises against oral anticoagulants after a peptic ulcer (stomach or duodenal sore) and requires precautions with methotrexate (ANSM SmPC Kardégic). Consequence: added bleeding; methotrexate toxicity. Mitigation: prescriber review before combining.
- Diuretics (urine-increasing drugs) and amikacin with ibuprofen lysinate (furosemide; amikacin, an injectable antibiotic): the label warns of weakened diuretics and dehydration-related kidney toxicity (NeoProfen label); amikacin clearance fell in preterm infants (Allegaert 2004). Consequence: kidney strain; amikacin build-up. Mitigation: kidney monitoring; longer amikacin intervals.
- Other antiplatelet drugs, heparins (injectable anticoagulants) and SSRIs (selective serotonin reuptake inhibitors, a class of antidepressants) with aspirin lysinate (clopidogrel, ticagrelor; enoxaparin; sertraline): its French label lists added bleeding with each (ANSM SmPC Kardégic). Consequence: bleeding. Mitigation: prescriber review and clinical monitoring.
- Glucocorticoids (steroid anti-inflammatory drugs) and valproic acid with aspirin lysinate (prednisolone; valproate, an anti-seizure drug): its French label lists added bleeding and altered salicylate levels with glucocorticoids, and raised valproate levels (ANSM SmPC Kardégic). Consequence: bleeding; valproate toxicity. Mitigation: valproate level checks.
- Anti-inflammatory pain relievers and antacids with aspirin lysinate (ibuprofen, naproxen; calcium carbonate): its French label lists added stomach ulcers and bleeding with the former, reduced aspirin absorption with the latter (ANSM SmPC Kardégic). Consequence: stomach bleeding; weaker aspirin effect. Mitigation: antacids taken 2+ hours apart.
Theoretical interactions (inferred from mechanism, not studied in humans):
- Aminoglycoside antibiotics (a class of injectable antibiotics: gentamicin, tobramycin, amikacin): inferred from both concentrating in kidney tubules, where high lysine is toxic in animals. Consequence: added kidney injury. Mitigation: pausing gram-dose lysine during the antibiotic course, with creatinine checks.
- Nonsteroidal anti-inflammatory drugs (common pain relievers: ibuprofen, naproxen, diclofenac): inferred additive kidney stress from reduced kidney blood flow plus lysine tubular load. Consequence: kidney strain, mainly with dehydration. Mitigation: short combined courses and adequate hydration.
- Glucose-lowering drugs (metformin, glibenclamide, insulin): inferred additive glucose lowering from lysine’s acute glucose-blunting effect. Consequence: lower glucose. Mitigation: glucose monitoring when starting.
- Arginine supplements and arginine-rich foods (L-arginine, nuts, seeds, chocolate): inferred from shared transporters. Consequence: weaker proposed antiviral effect. Mitigation: lower arginine intake during lysine use for cold sores.
- Vitamin D and other calcium-absorption enhancers: inferred additive calcium absorption. Consequence: excess calcium uptake with high calcium intake. Mitigation: serum calcium checks.
- Berberine and chromium: inferred additive glucose lowering. Consequence: lower glucose. Mitigation: glucose monitoring.
- Other mineral supplements alongside mineral lysinates (zinc, magnesium, calcium): inferred from summed mineral dose. Consequence: intake above mineral upper limits. Mitigation: totalling all mineral sources.
Populations who should avoid L-Lysinate:
- Kidney impairment: advised against in renal impairment (Drugs.com lysine monograph); inferred from lysine’s kidney tubule toxicity (Lo 1996); no human data in existing kidney disease. No lysine threshold published; aspirin lysinate’s is below.
- Liver impairment: advised against in hepatic impairment (Drugs.com lysine monograph); inferred from the liver performing nearly all lysine breakdown; no human harm data. No severity threshold has been published.
- Hyperlysinemia or hyperlysinuria (excess lysine in blood or urine): listed as a contraindication (Drugs.com lysine monograph); inferred from the inherited inability to break lysine down; no human harm data.
- Glutaric aciduria type 1: guideline treatment is a low-lysine diet (Boy 2023).
- Pyridoxine-dependent epilepsy (ALDH7A1 deficiency): guideline treatment includes lysine restriction (Coughlin 2021).
- Asthma provoked by aspirin or related anti-inflammatory drugs, active peptic ulcer, prior stomach bleeding or perforation on these drugs, or bleeding disorders (aspirin lysinate): contraindicated in the French label (ANSM SmPC Kardégic).
- Severe organ impairment and late pregnancy (aspirin lysinate): the same label contraindicates creatinine clearance (kidney filtering rate) below 30 mL/min, severe liver impairment, severe uncontrolled heart failure, mastocytosis (mast-cell overgrowth), and pregnancy beyond 24 weeks at doses above 100 mg/day (ANSM SmPC Kardégic).
Risk Mitigation Strategies
Doses and timings below follow common practice unless cited.
- Intake at or below 6 g/day: keeps intake within the no-observed-adverse-effect level (highest dose without observed harm) proposed by an industry-sponsored systematic review (Hayamizu 2020), limiting gastrointestinal upset.
- Split doses with meals: reduces nausea, stomach pain and diarrhea; single doses up to 7.5 g dose-dependently increased intestinal fluid (Baruffol 2014).
- Kidney checks with long-term gram dosing: creatinine and urinalysis at baseline, 3 months, then yearly; stop if creatinine rises or urine shows new glucose or protein, the pattern of lysine-associated kidney tubule injury (Lo 1996).
- Total calcium accounting: with calcium lysinate or other calcium sources, total intake within usual recommended amounts prevents excess calcium uptake from lysine-boosted absorption (Civitelli 1992).
- Screening for inherited lysine disorders: a diagnosis of glutaric aciduria type 1 (Boy 2023) or pyridoxine-dependent epilepsy (Coughlin 2021) rules out use, preventing toxic lysine build-up, per consensus guidelines; hyperlysinemia is a listed contraindication (Drugs.com lysine monograph).
- Parent-drug label for drug lysinates: following it limits the stomach injury, bleeding, heart risk and other harms ibuprofen and aspirin lysinates carry from their parent drugs, shown in a trial (Müller 1994) and meta-analyses (Bhala 2013; Baigent 2009).
- Pausing lysine during aminoglycoside courses: avoids possible additive kidney tubule injury during the antibiotic course.
Therapeutic Protocol
Timing, splitting, titration and duration below follow common practice unless cited.
- Cold-sore prevention dose: 1–3 g/day (Life Extension herpes protocol, from a lysine seller); up to 2 g/day, divided, with meals (Examine lysine page); 3 g/day (Griffith 1987); 1,248 mg/day effective, 624 mg/day not (McCune 1984).
- Antiviral alternative: a Cochrane review found long-term oral antivirals (acyclovir, valacyclovir) reduced cold-sore recurrences (Chi 2015); lysine and antivirals have never been compared head-to-head.
- Pauling–Rath vascular approach: Chris Kresser starts at 1 g/day each of lysine, proline and vitamin C, building to 3–5 g/day of each in divided doses (Kresser lipoprotein(a) episode), following Rath 1990.
- Stress and anxiety regimen: 2.64 g/day lysine plus 2.64 g/day arginine for one week (Smriga 2007).
- Mineral and drug lysinates: mineral lysinates are dosed by their mineral, so lysine intake follows the mineral dose; drug lysinates follow the drug label.
- Upper bound: 6.0 g/day no-observed-adverse-effect level, proposed through the International Council on Amino Acid Science, an association with amino acid interests (Cynober 2020).
- Time of day: supplements with meals (Examine lysine page); drug lysinates on an empty stomach for the fastest onset (Weiser 2019).
- Single or split dose: splitting two to three times daily is common, as in trial dosing three times daily (Griffith 1987) and Kresser’s divided doses.
- Half-life: no elimination half-life has been published for oral lysine; serum lysine roughly tripled within 2.5 hours of a single dose (Kalogeropoulou 2009), supporting split dosing.
- Genetic polymorphisms: no variant is known to change dosing in healthy people; glutaric aciduria type 1 (Boy 2023) and pyridoxine-dependent epilepsy (Coughlin 2021) exclude use per consensus guidelines, and hyperlysinemia is a listed contraindication (Drugs.com lysine monograph).
- Sex: no sex-specific doses exist; anxiety and cortisol responses differed between men and women (Smriga 2004).
- Age: no age-specific dosing exists; the low end of dose ranges is common practice for older adults with reduced kidney function.
- Baseline biomarkers: fortification benefits were shown only in people with low dietary lysine (Smriga 2004); serum lysine above 165 nmol/mL accompanied fewer recurrences (Thein 1984).
- Pre-existing conditions: kidney or liver impairment argues against use (Drugs.com lysine monograph); more frequent glucose checks when starting are common practice for people with diabetes on glucose-lowering drugs.
Discontinuation & Cycling
- Duration: no defined course; cold-sore trials used continuous intake for 6 months (Griffith 1987) and 12 months (Thein 1984), and lesions became more frequent after switching from lysine to placebo (Thein 1984), so any benefit appears tied to ongoing use.
- Withdrawal effects: none reported for lysine; the patient with kidney injury reported more energy after stopping (Lo 1996). Stopping long-term low-dose aspirin, as in aspirin lysinate, was linked to a 37% higher cardiovascular event rate in a cohort (Sundström 2017).
- Tapering: not required for lysine; stopping carries no known rebound beyond return of baseline cold-sore frequency. Drug lysinates follow the parent drug’s label.
- Cycling: no study has tested cycling, and all trials used continuous daily intake; there is no evidence that breaks preserve efficacy.
Sourcing and Quality
- Forms: L-lysine hydrochloride is the most studied form. Mineral lysinates include magnesium, calcium and zinc lysinate (EFSA scientific opinion) and ferrous lysinate sulfate (EFSA feed additive opinion); drug salts include ibuprofen (Ferrero-Cafiero 2015) and aspirin lysinate (Aarons 1989).
- Lysine content of mineral lysinates: labels state the mineral, not the lysine; lysine load scales with mineral dose, so trace-mineral zinc lysinate adds little lysine, while full-dose magnesium or calcium lysinate adds considerably more.
- Food grade versus feed grade: mineral lysinates are also made as animal-feed additives (EFSA feed additive opinion); only products labelled as human dietary supplements or medicines suit human use.
- Third-party testing: USP (United States Pharmacopeia) or NSF (independent certifier) seals, or ConsumerLab testing (ConsumerLab lysine review), confirm identity, dose and contaminant limits.
- Brands: Life Extension L-Lysine (620 mg capsules); Doctor’s Best High Absorption Magnesium (magnesium lysinate glycinate); calcium lysinate tested as CALNIFIT (Shankar 2018). Drug lysinates come from licensed pharmacies.
Practical Considerations
- Time to effect: ibuprofen lysinate acts within the first two hours (Seibel 2004); anxiety changes appeared after 1 week (Smriga 2007) to 3 months (Smriga 2004); cold-sore trials ran 6 months (Griffith 1987) and 12 months (Thein 1984).
- Common pitfalls: treating a mineral lysinate as a lysine dose; expecting a drug lysinate’s speed after meals (Weiser 2019); pairing lysine with arginine supplements for cold sores; exceeding 6 g/day.
- Regulatory status: EFSA judged magnesium, calcium and zinc L-lysinate of no safety concern as EU mineral sources at proposed levels (EFSA scientific opinion); in the US, ibuprofen lysine injection (NeoProfen) is an FDA-approved prescription drug (Drugs@FDA NeoProfen record).
- Cost and payer incentives: lysine is inexpensive, and generic oral antivirals for cold-sore prevention are also low-cost, so no systematic payer incentive favouring either option was identified.
Interaction with Foundational Habits
- Sleep: indirect, potentially supportive; no sleep trial exists, but lower trait anxiety with lysine plus arginine (Smriga 2007) could aid sleep onset. Practical: no timing restriction relative to bedtime is known.
- Nutrition: direct; a review reports Western diets supply 3–7 g/day of lysine (Holeček 2025), more from meat, dairy and legumes, less from cereal-heavy or some vegan diets. High-heat browning (Maillard reaction, sugar–protein binding) reduces usable lysine. Arginine-rich nuts, seeds and chocolate work against the cold-sore rationale.
- Exercise: none to potentiating at low intake; a review finds no trial showing extra strength or muscle from lysine on a lysine-sufficient diet (Holeček 2025), while a high-lysine diet raised strength by about 7.5% in young Indian men, both under- and well-nourished (Unni 2012).
- Stress management: direct, mixed; lysine plus arginine lowered trait anxiety, and basal salivary cortisol in men (Smriga 2007) but heightened hormonal responses during a public-speaking test in high-anxiety people (Jezova 2005), read by the authors as normalization.
Monitoring Protocol & Defining Success
Baseline testing before starting gram-level lysine or lysinate intake covers kidney function (serum creatinine with estimated glomerular filtration rate and a urinalysis), serum calcium when calcium lysinate or other calcium sources are involved, and HbA1c (3-month average blood-sugar marker) when blood-sugar effects are of interest. People using a drug lysinate follow the parent drug’s monitoring instead.
Ongoing monitoring repeats kidney tests and urinalysis at 3 months, then every 6–12 months while daily intake stays at gram levels; serum calcium is repeated at 3 months with calcium lysinate; HbA1c is repeated after 3 months. These cadences follow common practice rather than trial protocols, and results are read against the individual’s own baseline.
| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
|---|---|---|---|
| Serum creatinine | About 0.6–1.2 mg/dL, lab-specific (standard reference range) | Safety check: a rise stops use | Kidney failure followed long-term lysine in Lo 1996; pair with eGFR (estimated glomerular filtration rate, kidney filtering capacity); no fasting needed |
| Urinalysis (glucose, protein) | Negative for glucose and protein (standard reference range) | Safety check: new glucose or protein stops use | Early sign of tubule leakage (Fanconi syndrome) (Lo 1996); first-morning sample preferred |
| Serum calcium | 8.5–10.2 mg/dL (standard reference range) | Safety check with calcium lysinate or added calcium | Lysine raises calcium absorption (Civitelli 1992); fasting sample; pair with albumin |
| HbA1c | 4.0–5.6% (standard reference range) | Marker expected to change if blood-sugar effects occur | Evidence is weak and conflicted (Unni 2012); pair with fasting glucose; no fasting needed for HbA1c |
Qualitative markers:
- Cold-sore frequency, duration and severity, tracked in a diary against the prior year
- Perceived stress and anxiety, rated weekly
- Gastrointestinal comfort (nausea, bloating, stool changes)
- Energy and fluid balance (unusual thirst or urination can signal tubule problems)
Emerging Research
- Aspirin lysinate in Lynch syndrome (NCT02813824): Phase 3, 852 people with Lynch syndrome (inherited colorectal cancer risk) taking 100 or 300 mg/day acetylsalicylic acid lysinate or placebo for 4 years; endpoint: precancerous polyp recurrence. Completion December 2027. A positive result would strengthen the colorectal adenoma benefit; a null result would weaken it.
- Lysine as comparator in midlife depression (NCT06580145): Emory Phase 2 trial, 75 participants, 6 weeks of leucine versus lysine; endpoint: change in brain glutamate (an excitatory signaling chemical); completion 2029. Mood improvement in the lysine arm would strengthen the anxiety signal; no change would weaken it.
- Terminated blood-sugar trial (NCT04234581): a 12-week placebo-controlled trial of Lysulin (lysine, zinc, vitamin C; 3.3 g/day) on HbA1c in type 2 diabetes was terminated in 2020 by sponsor decision after 59 enrollments, no results posted, leaving Ranasinghe 2020 unreplicated.
- Cold-sore dose-response: reviewers call for longer trials above 1.2 g/day (Mailoo 2017); a positive trial at 3 g/day or more would strengthen the cold-sore item, another null trial would weaken it.
- Bone outcomes for calcium lysinate: the only trial lasted 8 weeks in 24 people using heel ultrasound (Shankar 2018); a controlled trial using dual-energy X-ray bone scans could confirm or refute an advantage over other calcium forms.
- Lysine–arginine balance and blood flow: a review proposes that a high lysine-to-arginine ratio may lower nitric oxide and tissue perfusion (Holeček 2025); human studies could reveal a vascular risk not yet seen in short trials.
Conclusion
L-lysinate is not a new nutrient but a delivery form: a salt or mineral compound releasing ordinary lysine in the gut. Its health case rests mostly on studies of plain lysine, plus a few of the lysinate form itself.
For a health-focused adult, the best-known use, preventing cold-sore flare-ups, remains contested: some higher-dose studies reported fewer outbreaks, while others and a major review found no benefit. Signals for calmer stress responses, better calcium uptake and gentler blood-sugar rises come from small, short and often indirect studies, several run by a lysine manufacturer. As a drug carrier, lysinate speeds pain-reliever uptake, though the largest direct comparison found no advantage over the standard tablet; aspirin lysinate is approved in France against repeat heart attacks and strokes on plain-aspirin evidence. Lysine’s own effects on arteries and on sugar damage to proteins remain theoretical.
The safety picture is reassuring at ordinary supplement amounts. Digestive upset, the main side effect, was no more common than with placebo across combined studies, and up to about six grams daily appears well tolerated. A single report of serious kidney damage after years of use, plus animal findings, makes kidney health the main open safety question. Drug lysinates also carry the original drug’s stomach, kidney, bleeding and heart risks, and the picture differs for people with inherited lysine disorders or kidney or liver disease.
The evidence base is thin, dated in places and partly industry-linked, so expected gains for a well-nourished, health-focused adult are modest and uncertain.